The road to enlightenment or an uphill struggle?

Five years ago when CD19 bispecifics and CAR-T cell therapies were all the rage, I doubt few people anticipated these agents would wind up being evaluated outside of cancer indications in areas such as autoimmune diseases.

Part of the reason, I suspect, lies in the very Yin and Yang nature of the underlying biology.

Chemists creating antibodies against targets relevant to both often create agonists and antagonists, reflecting different opportunities in each.

With CD19/CD20/BCMA CAR-Ts and bispecifics, however, the same product can be used for both because the initial goal is to simply wipe out all the pathogenic B cells or plasma cells and reset the immune system. Nifty, eh?

In our latest conference preview we highlight over a dozen different products to watch out for and look at some of the novel and emerging early stage approaches coming through beyond the obvious.

While there have been some dramatic and encouraging early signs in clinical trials, the road to approval success might be longer than some observers expect because there’s still a matter of phase 2 and 3 trials to go where long term follow-up might shake out some unexpected findings. “Optimistically cautious” is how one expert described his view of this fledgling world to BSB.

Curious to learn more?  Check out the article below…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by